Loading…
Acumen Pharmaceuticals, Inc. is projected to rise to $2.82 by 2027, a +7% move from its current price of $2.63. ABOS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.53 | $2.63 | $2.74 | +0.02% |
| Jul 13 | $2.49 | $2.63 | $2.78 | +0.03% |
| Jul 14 | $2.46 | $2.63 | $2.82 | +0.05% |
| Jul 15 | $2.43 | $2.63 | $2.85 | +0.07% |
| Jul 16 | $2.41 | $2.63 | $2.88 | +0.09% |
| Jul 17 | $2.39 | $2.63 | $2.90 | +0.10% |
| Jul 18 | $2.37 | $2.63 | $2.92 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.37 | $2.63 | $2.92 | +0.12% |
| Week 2 | $2.27 | $2.64 | $3.06 | +0.24% |
| Week 3 | $2.20 | $2.64 | $3.17 | +0.36% |
| Week 4 | $2.14 | $2.64 | $3.26 | +0.49% |
| Week 5 | $2.09 | $2.65 | $3.35 | +0.61% |
| Week 6 | $2.05 | $2.65 | $3.43 | +0.73% |
| Week 7 | $2.01 | $2.65 | $3.50 | +0.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of Alzheimer's disease. It centers its work on sabirnetug (ACU193), a targeted immunotherapy drug candidate in the Phase 2 ALTITUDE-AD clinical trial.
Acumen has collaboration and license agreements with Halozyme, Inc. for a subcutaneous formulation of sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease.
The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Acumen Pharmaceuticals, Inc. (ABOS) is a healthcare company trading on public markets. The stock is currently priced at $2.57, with a market cap of $185.62M, and it ranks 3879 by market capitalization.
Forecasts project a near-term path with a 2026 average price of $2.57 and a longer-term rise to higher averages, including a 2030 average of $4.21 and a 2050 average of $18.68. The implied ROIs move from 0% in 2026 to 63.9% by 2030 and up to 626.9% by 2050, with a bullish sentiment in the longer horizon.
These figures depict an upside trajectory over the forecast horizon, though they remain estimates and are not guarantees.
A major floor 27.9% below — a decisive break under it would weaken the trend.
The nearest floor, 18.3% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 28.1% above — clearing it would confirm fresh momentum.
Key ABOS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABOS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.66 | Sell | $2.66 | Sell |
| MA 10 | $2.64 | Sell | $2.61 | Buy |
| MA 20 | $2.48 | Buy | $2.53 | Buy |
| MA 50 | $2.43 | Buy | $2.49 | Buy |
| MA 100 | $2.61 | Buy | $2.46 | Buy |
| MA 200 | $2.32 | Buy | $2.31 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.95 | Neutral |
| Stoch RSI (14) | 55.53 | Neutral |
| CCI (20) | 56.97 | Neutral |
| Williams %R (14) | -25.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 9.13 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 75.00 | Neutral |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 0.22 | Buy |
| Ultimate (7,14,28) | 51.52 | Neutral |
| Momentum (10) | 0.42 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 2.68 | Sell |
| ADX (14) | 13.55 | Neutral |
| ATR (14) | 0.10 | Info |
The near-term technical picture is bullish.
RSI14 is 50, with the 50-day simple moving average at $2.42 and the 200-day simple moving average at $2.29.
Support is noted at $2.15 and resistance at $2.77, framing a 30-day trading range of $1.96 to $3.37. Annualized volatility stands at 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.72 | $2.63 | $3.62 | 0% | Neutral | |
| $2.15 | $2.82 | $3.96 | +7% | Neutral | |
| $2.04 | $2.79 | $4.12 | +6% | Neutral | |
| $2.04 | $2.90 | $4.45 | +10% | Neutral | |
| $2.67 | $3.92 | $6.22 | +49% | Bullish | |
| $2.96 | $4.47 | $7.30 | +70% | Bullish | |
| $2.91 | $4.51 | $7.55 | +71% | Bullish | |
| $3.16 | $5.03 | $8.62 | +91% | Bullish | |
| $2.88 | $4.71 | $8.24 | +79% | Bullish | |
| $2.82 | $4.72 | $8.41 | +79% | Bullish | |
| $3.68 | $6.90 | $13.32 | +162% | Bullish | |
| $6.99 | $15.54 | $33.57 | +491% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.72 | $2.63 | $3.07 | +0.00% |
| August 2026 | $2.12 | $2.53 | $3.13 | -3.65% |
| September 2026 | $2.21 | $2.67 | $3.35 | +5.44% |
| October 2026 | $2.22 | $2.70 | $3.44 | +1.13% |
| November 2026 | $2.18 | $2.67 | $3.44 | -1.14% |
| December 2026 | $2.25 | $2.79 | $3.62 | +4.35% |
Click any year to see its month-by-month ABOS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ABOS to range from $1.72 to $3.62 through 2026. The $2.63 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ABOS price prediction for 2027 points to an average of $2.82 (low $2.15, high $3.96) — a potential gain of +7% on today's $2.63. A consolidation phase looks the most probable path here.
In 2028, ABOS is projected to trade between $2.04 and $4.12, averaging $2.79 — a potential gain of +6% from today's $2.63. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
Acumen Pharmaceuticals, Inc.'s 2029 outlook centres on $2.90, within a $2.04 to $4.45 range. That is up +4% on the projected 2028 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, ABOS could reach as high as $6.22, with a base case around $3.92 and support toward $2.67 — roughly +49% from $2.63. Momentum favours further upside here.
Expect ABOS to range from $2.96 to $7.30 through 2031. The $4.47 average target implies a +70% move from current prices. That is up +14% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ABOS price prediction for 2032 points to an average of $4.51 (low $2.91, high $7.55) — a potential gain of +71% on today's $2.63. Momentum favours further upside here.
In 2033, ABOS is projected to trade between $3.16 and $8.62, averaging $5.03 — a potential gain of +91% from today's $2.63. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Acumen Pharmaceuticals, Inc.'s 2034 outlook centres on $4.71, within a $2.88 to $8.24 range. That is -6% versus the projected 2033 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2035, ABOS could reach as high as $8.41, with a base case around $4.72 and support toward $2.82 — roughly +79% from $2.63. Buyers look set to stay in control over this stretch.
Expect ABOS to range from $3.68 to $13.32 through 2040. The $6.90 average target implies a +162% move from current prices. That is up +46% on the projected 2035 average. Momentum favours further upside here.
The ABOS price prediction for 2050 points to an average of $15.54 (low $6.99, high $33.57) — a potential gain of +491% on today's $2.63. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABOS today (≈ 380.228137 ABOS) could be worth
$5,907.39
+$4,907.39 (+491%) by 2050 · US Dollar
Based on the average projected ABOS price of $15.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABOSwould be worth at today's price.
$1,000 invested in ABOS on Jul 10, 2025 (≈ 769.230797 ABOS) would be worth
$2,023.08
+$1,023.08 (+102.3%) today · 2.02× · US Dollar
Based on a ABOS entry price of $1.3 vs. today's $2.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.74 | $959.85 | -4.0% |
| 1 month ago | $2.24 | $1,174.11 | +17.4% |
| 3 months ago | $2.47 | $1,064.78 | +6.5% |
| 6 months ago | $1.72 | $1,529.07 | +52.9% |
| 1 year ago | $1.3 | $2,023.08 | +102.3% |
| All time (5.0y) ago | $18.5 | $142.16 | -85.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABOS forecast.
Our base-case forecast reaches $5.30 around 2040.
Implied market cap at $5.30: $382.81M
The multi-year forecast points to a bullish trajectory through the late 2020s and into the 2030s.
For 2030, the avg price is $4.21 with a ROI of 63.9% and sentiment BULLISH.
By 2040, the avg price is $7.78 with a ROI of 202.6% and sentiment BULLISH.
In 2050, the avg price is $18.68 with a ROI of 626.9% and sentiment BULLISH. These figures illustrate a steady, long-run upside, but they are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.21 with a min of $2.85, a max of $6.76, a ROI of 63.9%, and a bullish sentiment.
Forecasts show potential upside with average prices rising toward $4.21 by 2030 and $18.68 by 2050, with ROIs of 63.9% and 626.9% respectively; these are estimates, not guarantees.
According to the forecast, the 2033 max is $9.47 and the 2040 max is $15.23; the 2040 max exceeds $10, so a move above $10 is possible within the forecast horizon.
The thirtyDayRange runs from $1.96 to $3.37.
Current price is $2.57 and market cap is $185.62M; the current rank is 3879.
Acumen Pharmaceuticals, Inc. Community Discussion
0Share your Acumen Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.